A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2017
At a glance
- Drugs E 6011 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Sponsors EA Pharma; Eisai Co Ltd
- 10 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Feb 2017 Planned number of patients changed from 24 to 21.
- 23 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2017.